Published in J Biol Chem on October 07, 2013
Surviving at a distance: organ specific metastasis. Trends Cancer (2015) 0.90
The role of Cullin3-mediated ubiquitination of the catalytic subunit of PP2A in TRAIL signaling. Cell Cycle (2014) 0.79
LB100, a small molecule inhibitor of PP2A with potent chemo- and radio-sensitizing potential. Cancer Biol Ther (2015) 0.79
p21-activated Kinases (PAKs) Mediate the Phosphorylation of PREX2 Protein to Initiate Feedback Inhibition of Rac1 GTPase. J Biol Chem (2015) 0.77
Caspase-8 tyrosine-380 phosphorylation inhibits CD95 DISC function by preventing procaspase-8 maturation and cycling within the complex. Oncogene (2016) 0.76
Selective activators of protein phosphatase 5 target the auto-inhibitory mechanism. Biosci Rep (2015) 0.76
Death receptors: signaling and modulation. Science (1998) 16.95
Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity (1995) 10.59
Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem J (2001) 9.40
Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science (1997) 6.82
The receptor for the cytotoxic ligand TRAIL. Science (1997) 6.39
Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem (1996) 6.22
Serine/threonine phosphatases: mechanism through structure. Cell (2009) 6.19
An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science (1997) 6.10
Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell (2009) 5.24
KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet (1997) 4.46
TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J (1997) 4.28
c-Src and cooperating partners in human cancer. Cancer Cell (2004) 4.22
Overview of cell death signaling pathways. Cancer Biol Ther (2005) 4.22
Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med (2007) 3.99
Protein phosphatase 2A regulatory subunits and cancer. Biochim Biophys Acta (2008) 3.74
Ligand-independent redistribution of Fas (CD95) into lipid rafts mediates clonotypic T cell death. Nat Immunol (2004) 2.55
TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL. Curr Biol (1997) 1.68
An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis. J Biol Chem (2002) 1.65
Src kinase phosphorylates Caspase-8 on Tyr380: a novel mechanism of apoptosis suppression. EMBO J (2006) 1.64
Targeting Src in breast cancer. Ann Oncol (2008) 1.57
TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling. FEBS Lett (1998) 1.54
Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol (2006) 1.52
Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents. J Clin Oncol (2005) 1.44
Identification of inhibitors of TRAIL-induced death (ITIDs) in the TRAIL-sensitive colon carcinoma cell line SW480 using a genetic approach. J Biol Chem (2001) 1.42
Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation. Cell Death Differ (2003) 1.41
TRAIL as a target in anti-cancer therapy. Cancer Lett (2009) 1.39
Lipid rafts and nonrafts mediate tumor necrosis factor related apoptosis-inducing ligand induced apoptotic and nonapoptotic signals in non small cell lung carcinoma cells. Cancer Res (2007) 1.31
Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study. J Clin Oncol (2009) 1.30
Erythroid differentiation sensitizes K562 leukemia cells to TRAIL-induced apoptosis by downregulation of c-FLIP. Mol Cell Biol (2003) 1.17
Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study. Clin Cancer Res (2009) 1.16
Rare loss-of-function mutation of a death receptor gene in head and neck cancer. Cancer Res (1998) 1.11
Activation of the Akt survival pathway contributes to TRAIL resistance in cancer cells. PLoS One (2010) 1.08
c-Cbl acts as a mediator of Src-induced activation of the PI3K-Akt signal transduction pathway during TRAIL treatment. Cell Signal (2010) 1.05
Src and ADAM-17-mediated shedding of transforming growth factor-alpha is a mechanism of acute resistance to TRAIL. Cancer Res (2008) 1.04
Apoptotic death of tumor cells correlates with chemosensitivity, independent of p53 or bcl-2. Clin Cancer Res (1996) 1.03
The effect of a PP2A inhibitor on the nuclear receptor corepressor pathway in glioma. J Neurosurg (2010) 1.01
A RNA interference screen identifies the protein phosphatase 2A subunit PR55gamma as a stress-sensitive inhibitor of c-SRC. PLoS Genet (2007) 0.95
Kinome profiling of non-canonical TRAIL signaling reveals RIP1-Src-STAT3-dependent invasion in resistant non-small cell lung cancer cells. J Cell Sci (2012) 0.92
Cross-talk between serine/threonine protein phosphatase 2A and protein tyrosine phosphatase 1B regulates Src activation and adhesion of integrin αIIbβ3 to fibrinogen. J Biol Chem (2010) 0.83
BORIS, a novel male germ-line-specific protein associated with epigenetic reprogramming events, shares the same 11-zinc-finger domain with CTCF, the insulator protein involved in reading imprinting marks in the soma. Proc Natl Acad Sci U S A (2002) 2.62
Murine ccl2/cx3cr1 deficiency results in retinal lesions mimicking human age-related macular degeneration. Invest Ophthalmol Vis Sci (2007) 2.36
Neurofibromatosis type 2. Lancet (2009) 2.24
Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Sci Transl Med (2013) 2.06
Overexpression of yes-associated protein contributes to progression and poor prognosis of non-small-cell lung cancer. Cancer Sci (2010) 2.04
Characterization of the blood-brain barrier of metastatic and primary malignant neoplasms. J Neurosurg (2013) 1.86
Elevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with metastatic colorectal cancer. Clin Cancer Res (2005) 1.84
Involvement of MKP-1 and Bcl-2 in acquired cisplatin resistance in ovarian cancer cells. Cell Cycle (2009) 1.80
Hsa-miR-125a-3p and hsa-miR-125a-5p are downregulated in non-small cell lung cancer and have inverse effects on invasion and migration of lung cancer cells. BMC Cancer (2010) 1.72
Retracted Application and implementation of selective tissue microdissection and proteomic profiling in neurological disease. Neurosurgery (2009) 1.69
Proteome analysis of microdissected formalin-fixed and paraffin-embedded tissue specimens. J Histochem Cytochem (2007) 1.66
DR5 knockout mice are compromised in radiation-induced apoptosis. Mol Cell Biol (2005) 1.55
ERK-dependent MKP-1-mediated cisplatin resistance in human ovarian cancer cells. Cancer Res (2007) 1.52
von Hippel-Lindau disease-associated hemangioblastomas are derived from embryologic multipotent cells. PLoS Med (2007) 1.52
A functional polymorphism in the EGF gene is found with increased frequency in glioblastoma multiforme patients and is associated with more aggressive disease. Cancer Res (2004) 1.48
Identification and characterization of a novel member of olfactomedin-related protein family, hGC-1, expressed during myeloid lineage development. Gene (2002) 1.45
Hypoxia-inducible factor-1α expression indicates poor prognosis in myelodysplastic syndromes. Leuk Lymphoma (2012) 1.43
Developmental arrest of angioblastic lineage initiates tumorigenesis in von Hippel-Lindau disease. Cancer Res (2003) 1.38
Stochastic cancer progression driven by non-clonal chromosome aberrations. J Cell Physiol (2006) 1.37
Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells. Biochem Biophys Res Commun (2010) 1.37
Clinical and molecular analysis of disseminated hemangioblastomatosis of the central nervous system in patients without von Hippel-Lindau disease. Report of four cases. J Neurosurg (2002) 1.35
Mitogen-activated protein kinase phosphatase-1 is required for cisplatin resistance. Cancer Res (2006) 1.35
TNFSF10 (TRAIL), a p53 target gene that mediates p53-dependent cell death. Cancer Biol Ther (2008) 1.34
Inhibition of serine/threonine phosphatase PP2A enhances cancer chemotherapy by blocking DNA damage induced defense mechanisms. Proc Natl Acad Sci U S A (2009) 1.34
Hemangioblastomas share protein expression with embryonal hemangioblast progenitor cell. Cancer Res (2006) 1.34
New syndrome of paraganglioma and somatostatinoma associated with polycythemia. J Clin Oncol (2013) 1.32
Prospective study of thymic carcinoids in patients with multiple endocrine neoplasia type 1. J Clin Endocrinol Metab (2003) 1.28
Non-islet origin of pancreatic islet cell tumors. J Clin Endocrinol Metab (2004) 1.24
The role of mitogen-activated protein kinase phosphatase-1 in oxidative damage-induced cell death. Cancer Res (2006) 1.23
Edema is a precursor to central nervous system peritumoral cyst formation. Ann Neurol (2005) 1.23
The phosphatase MKP1 is a transcriptional target of p53 involved in cell cycle regulation. J Biol Chem (2003) 1.20
Novel zinc-based fixative for high quality DNA, RNA and protein analysis. Nucleic Acids Res (2007) 1.18
Protein patterns and proteins that identify subtypes of glioblastoma multiforme. Oncogene (2004) 1.18
N-CoR pathway targeting induces glioblastoma derived cancer stem cell differentiation. Cell Cycle (2007) 1.17
Interleukin 7/interleukin 7 receptor induce c-Fos/c-Jun-dependent vascular endothelial growth factor-D up-regulation: a mechanism of lymphangiogenesis in lung cancer. Eur J Cancer (2009) 1.14
Missense mutations in the NF2 gene result in the quantitative loss of merlin protein and minimally affect protein intrinsic function. Proc Natl Acad Sci U S A (2011) 1.13
Bim protein degradation contributes to cisplatin resistance. J Biol Chem (2011) 1.13
A novel EPAS1/HIF2A germline mutation in a congenital polycythemia with paraganglioma. J Mol Med (Berl) (2012) 1.13
MicroRNA-449a is downregulated in non-small cell lung cancer and inhibits migration and invasion by targeting c-Met. PLoS One (2013) 1.12
Proteome analysis of microdissected tumor tissue using a capillary isoelectric focusing-based multidimensional separation platform coupled with ESI-tandem MS. Anal Chem (2005) 1.12
Effects of VHL deficiency on endolymphatic duct and sac. Cancer Res (2005) 1.11
Cisplatin resistance associated with PARP hyperactivation. Cancer Res (2013) 1.11
Decreased glucocerebrosidase activity in Gaucher disease parallels quantitative enzyme loss due to abnormal interaction with TCP1 and c-Cbl. Proc Natl Acad Sci U S A (2010) 1.09
Coexpression of erythropoietin and erythropoietin receptor in von Hippel-Lindau disease-associated renal cysts and renal cell carcinoma. Clin Cancer Res (2005) 1.09
The role of MAP kinases and MAP kinase phosphatase-1 in resistance to breast cancer treatment. Cancer Metastasis Rev (2010) 1.09
Comedo-ductal carcinoma in situ: A paradoxical role for programmed cell death. Cancer Biol Ther (2008) 1.08
Activation of the Akt survival pathway contributes to TRAIL resistance in cancer cells. PLoS One (2010) 1.08
Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas. Blood (2013) 1.07
Overexpression of TRIM24 correlates with tumor progression in non-small cell lung cancer. PLoS One (2012) 1.07
Histone deacetylase inhibitors prevent the degradation and restore the activity of glucocerebrosidase in Gaucher disease. Proc Natl Acad Sci U S A (2011) 1.06
Evidence that tumor necrosis factor-related apoptosis-inducing ligand induction by 5-Aza-2'-deoxycytidine sensitizes human breast cancer cells to adriamycin. Cancer Res (2007) 1.06
Hypoxia induced CCR7 expression via HIF-1alpha and HIF-2alpha correlates with migration and invasion in lung cancer cells. Cancer Biol Ther (2009) 1.06
Comparative proteomic profiles of meningioma subtypes. Cancer Res (2006) 1.05
Dysgerminoma in a case of 46, XY pure gonadal dysgenesis (Swyer syndrome): a case report. Diagn Pathol (2011) 1.05
MicroRNA HSA-miR-125a-5p induces apoptosis by activating p53 in lung cancer cells. Exp Lung Res (2011) 1.04
Identification of a novel synthetic triterpenoid, methyl-2-cyano-3,12-dioxooleana-1,9-dien-28-oate, that potently induces caspase-mediated apoptosis in human lung cancer cells. Mol Cancer Ther (2002) 1.04
The changing role of pathology in breast cancer diagnosis and treatment. Pathobiology (2011) 1.02
Novel anti-filamin-A antibody detects a secreted variant of filamin-A in plasma from patients with breast carcinoma and high-grade astrocytoma. Cancer Sci (2009) 1.02
Proteins and protein pattern differences between glioma cell lines and glioblastoma multiforme. Clin Cancer Res (2005) 1.02
The effect of a PP2A inhibitor on the nuclear receptor corepressor pathway in glioma. J Neurosurg (2010) 1.01
Expression of ezrin correlates with malignant phenotype of lung cancer, and in vitro knockdown of ezrin reverses the aggressive biological behavior of lung cancer cells. Tumour Biol (2012) 1.01
Hereditary pituitary hyperplasia with infantile gigantism. J Clin Endocrinol Metab (2011) 1.01
Expression of stem cells markers in ocular hemangioblastoma associated with von Hippel-Lindau (VHL) disease. Mol Vis (2005) 1.00
Hypoxia-inducible factor signaling in pheochromocytoma: turning the rudder in the right direction. J Natl Cancer Inst (2013) 0.98
Racial disparity in breast cancer and functional germ line mutation in galectin-3 (rs4644): a pilot study. Cancer Res (2008) 0.98
Missense mutations in the human SDHB gene increase protein degradation without altering intrinsic enzymatic function. FASEB J (2012) 0.98
Association of TERT promoter mutation 1,295,228 C>T with BRAF V600E mutation, older patient age, and distant metastasis in anaplastic thyroid cancer. J Clin Endocrinol Metab (2015) 0.98
Proteomic analysis of inclusion body myositis. J Neuropathol Exp Neurol (2006) 0.97
Overexpressions of RACK1 and CD147 associated with poor prognosis in stage T1 pulmonary adenocarcinoma. Ann Surg Oncol (2012) 0.96
β-Catenin signaling initiates the activation of astrocytes and its dysregulation contributes to the pathogenesis of astrocytomas. Proc Natl Acad Sci U S A (2012) 0.96
Developmental effects of von Hippel-Lindau gene deficiency. Ann Neurol (2004) 0.96
Proteostasis modulators prolong missense VHL protein activity and halt tumor progression. Cell Rep (2013) 0.96
Histone deacetylase inhibitors increase glucocerebrosidase activity in Gaucher disease by modulation of molecular chaperones. Proc Natl Acad Sci U S A (2012) 0.95
Clinicopathological significance and prognostic value of DNA methyltransferase 1, 3a, and 3b expressions in sporadic epithelial ovarian cancer. PLoS One (2012) 0.95
Pharmacologic modulation of serine/threonine phosphorylation highly sensitizes PHEO in a MPC cell and mouse model to conventional chemotherapy. PLoS One (2011) 0.95
Prospective natural history study of central nervous system hemangioblastomas in von Hippel-Lindau disease. J Neurosurg (2014) 0.94
Overexpression of JAM-A in non-small cell lung cancer correlates with tumor progression. PLoS One (2013) 0.94
Von Hippel-Lindau gene deletion and expression of hypoxia-inducible factor and ubiquitin in optic nerve hemangioma. Trans Am Ophthalmol Soc (2004) 0.94
Somatic mutations in VHL germline deletion kindred correlate with mild phenotype. Ann Neurol (2004) 0.94
Sp1-mediated TRAIL induction in chemosensitization. Cancer Res (2008) 0.94
P120-catenin isoforms 1 and 3 regulate proliferation and cell cycle of lung cancer cells via β-catenin and Kaiso respectively. PLoS One (2012) 0.94
Mitogen activated protein kinase phosphatases and cancer. Cancer Biol Ther (2010) 0.93
Somatic VHL gene alterations in MEN2-associated medullary thyroid carcinoma. BMC Cancer (2006) 0.93
Inhibition of cytoplasmic GSK-3β increases cisplatin resistance through activation of Wnt/β-catenin signaling in A549/DDP cells. Cancer Lett (2013) 0.93
Germ-line PHD1 and PHD2 mutations detected in patients with pheochromocytoma/paraganglioma-polycythemia. J Mol Med (Berl) (2014) 0.93
Downregulation of Mig-6 in nonsmall-cell lung cancer is associated with EGFR signaling. Mol Carcinog (2011) 0.92
Clinical significance and biological roles of SPAG9 overexpression in non-small cell lung cancer. Lung Cancer (2013) 0.92
Clinical and prognostic significance of Yes-associated protein in colorectal cancer. Tumour Biol (2013) 0.92
Post-translational regulation of mitogen-activated protein kinase phosphatase-2 (MKP-2) by ERK. Cell Cycle (2010) 0.92